Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.
On Holding receives an Outperform rating with a $37 price target from Telsey Advisory Group, banking on strong Q1 pace of product launches and margin growth.
Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration and significant revenue potential.
Henry Schein reports Q1 adjusted EPS at $1.10, down 9% Y/Y, with sales at $3.17 billion, up 3.7%. Guidance projects 2024 sales growth at 8%-10%, reaffirming adjusted EPS guidance of $5.00-$5.16. William Blair attributes the EPS beat to margin expansion driven by technology and value-added services.
Shopify (SHOP) will report Q1 earnings on Wednesday. Technical indicators suggest a bullish trend, while analysts foresee a downside potential of -17.70%.